Quince Therapeutics, Inc.
QNCX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $36 | $35 | $0 | $16 |
| Gross Profit | -$36 | -$35 | $0 | -$16 |
| % Margin | – | – | – | – |
| R&D Expenses | $8,083 | $6,553 | $8,145 | $5,825 |
| G&A Expenses | $0 | $3,342 | $4,789 | $0 |
| SG&A Expenses | $3,245 | $3,342 | $4,789 | $4,268 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$35 | $1,924 | $0 |
| Operating Expenses | $11,328 | $9,860 | $14,858 | $10,093 |
| Operating Income | -$11,364 | -$9,895 | -$14,858 | -$10,109 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$2,124 | -$6,087 | -$125 | -$2,342 |
| Pre-Tax Income | -$13,488 | -$15,982 | -$14,983 | -$12,451 |
| Tax Expense | -$46 | $67 | $47 | $7 |
| Net Income | -$13,442 | -$16,049 | -$15,030 | -$12,458 |
| % Margin | – | – | – | – |
| EPS | -0.25 | -0.34 | -0.34 | -0.28 |
| % Growth | 26.5% | 0% | -21.4% | – |
| EPS Diluted | -0.25 | -0.34 | -0.34 | -0.28 |
| Weighted Avg Shares Out | 53,951 | 46,686 | 43,941 | 43,262 |
| Weighted Avg Shares Out Dil | 53,951 | 46,686 | 43,941 | 43,262 |
| Supplemental Information | – | – | – | – |
| Interest Income | $300 | $311 | $406 | $536 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $36 | $35 | $32 | $16 |
| EBITDA | -$13,452 | -$15,947 | -$12,902 | -$12,435 |
| % Margin | – | – | – | – |